The optimal dose of metformin to control conversion to diabetes in patients with prediabetes: A meta-analysis

This study aims to investigate the optimal dose of metformin for controlling the transition to diabetes in patients diagnosed with prediabetes. We systematically searched randomized controlled trials (RCTs) in CNKI, Wanfang, VIP, SinoMed, Scopus, PubMed, Embase, Cochrane Library, Web of Science, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of diabetes and its complications 2024-10, Vol.38 (10), p.108846, Article 108846
Hauptverfasser:	Yi, Xiaoyan, Pan, Yongliang, Peng, Huan, Ren, Mengru, Jia, Qin, Wang, Bing
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Bias Blood Glucose - analysis Blood Glucose - drug effects Blood Glucose - metabolism Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Disease Progression Dose-Response Relationship, Drug Glucose Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Intervention Meta-analysis Metformin Metformin - administration & dosage Metformin - therapeutic use Optimal dose Prediabetes Prediabetic State - blood Prediabetic State - complications Prediabetic State - drug therapy Randomized Controlled Trials as Topic Research methodology Risk assessment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This study aims to investigate the optimal dose of metformin for controlling the transition to diabetes in patients diagnosed with prediabetes. We systematically searched randomized controlled trials (RCTs) in CNKI, Wanfang, VIP, SinoMed, Scopus, PubMed, Embase, Cochrane Library, Web of Science, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) from inception to February 2024. Meta-analysis was conducted using RevMan 5.4 software. We included 25 randomized controlled trials comprising 2437 patients. The results of the meta-analysis revealed that compared to dose groups of 500 mg/d, 850 mg/d, 1000 mg/d, 1500 mg/d, 1700 mg/d, and 2000 mg/d, a dosage of 750 mg/d of metformin significantly reduced the incidence of diabetes in patients (risk ratio [RR] = 0.21, 95 % confidence interval [CI]: 0.11, 0.41; p
ISSN:	1056-8727 1873-460X 1873-460X
DOI:	10.1016/j.jdiacomp.2024.108846